FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation

The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased dramatically worldwide and, subsequently, also the risk of developing non-alcoholic steatohepatitis (NASH), hepatic fibrosis, cirrhosis and cancer. Today, weight loss is the only available treatment, but administration of fibr...

Descripción completa

Detalles Bibliográficos
Autores principales: Keinicke, Helle, Sun, Gao, Mentzel, Caroline M Junker, Fredholm, Merete, John, Linu Mary, Andersen, Birgitte, Raun, Kirsten, Kjaergaard, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424338/
https://www.ncbi.nlm.nih.gov/pubmed/32688339
http://dx.doi.org/10.1530/EC-20-0152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424338/
https://www.ncbi.nlm.nih.gov/pubmed/32688339
http://dx.doi.org/10.1530/EC-20-0152

Ejemplares similares